SCHEMBL4112012

SCHEMBL4112012

N#Cc1cccc(C#CC(=O)N2CCc3ccccc3C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
GRM5 P41594 2/20 0.47
NOTUM Q6P988 1/20 0.47
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
TRPA1 O75762 1/20 0.45
NAMPT P43490 4/20 0.45
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 1/20 0.44
CYP1A2 P05177 1/20 0.44
HTR1A P08908 2/20 0.44
DRD2 P14416 1/20 0.44
HTR2A P28223 1/20 0.44
SLC6A4 P31645 1/20 0.44
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116705 0.85 NOTUM (0.55) GRM5NOTUMMAPTMEN1KMT2A
SCHEMBL4105538 0.85 ALDH1A1 (0.53) TAS1R3TAS1R1TAS1R2GRM5NOTUM
SCHEMBL4111987 0.85 NPC1 (0.56) TAS1R3TAS1R1TAS1R2GRM5NOTUM
SCHEMBL4106020 0.82 NPC1 (0.58) TAS1R3TAS1R1TAS1R2GRM5NOTUM
SCHEMBL4124894 0.81 TAS1R3 (0.60) TAS1R3TAS1R1TAS1R2NOTUMMAPT
SCHEMBL4106025 0.80 RAB9A (0.56) GRM5NOTUMMAPTMEN1KMT2A
SCHEMBL4110501 0.80 RAB9A (0.57) TAS1R3TAS1R1TAS1R2GRM5NOTUM
SCHEMBL4106224 0.78 NPC1 (0.48) TAS1R3TAS1R1TAS1R2GRM5MEN1
SCHEMBL4105991 0.78 NPC1 (0.56) GRM5NOTUMMAPTMEN1KMT2A
SCHEMBL4119191 0.78 RAB9A (0.56) TAS1R3TAS1R1TAS1R2NOTUMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US claimed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP claimed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO claimed
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US disclosed
EP-1968938-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-09-17 EP disclosed
WO-2007079957-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS PCCA, PPARA, PTGES TAS1R3 3432/4885TAS1R1 4064/4885TAS1R2 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.